Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Alternative complement pathway" patented technology

The alternative pathway of the complement system is an innate component of the immune system's natural defense against infections. The alternative pathway is one of three complement pathways that opsonize and kill pathogens. The pathway is triggered when the C3b protein directly binds a microbe. It can also be triggered by foreign materials and damaged tissues.

Methods for Modulating Complement Factor B Expression

PendingUS20260174765A1Carbohydrate active ingredientsCapsule deliveryDiseaseComplement factor I
Provided herein are methods of ameliorating a disease or disorder associated with dysregulation of the alternative complement pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
Owner:IONIS PHARMACEUTICALS INC

Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof

PendingUS20260184689A1Benzoic acidPharmaceutical drug
Disclosed in the present invention are a piperidine-substituted benzoic acid compound, and a pharmaceutical composition and the use thereof. The piperidine-substituted benzoic acid compound of the present invention is a compound as shown in formula (I) or a stereoisomer, a tautomer or an isotopic label thereof, or a pharmaceutically acceptable salt of any one of the foregoing. The compound has a good inhibitory activity on complement factor B, a good affinity activity on complement factor B, and a hemolytic activity and an inhibitory activity of an alternative complement pathway.
Owner:SHANGHAI YISHENG BIOPHARMACEUTICAL CO LTD

Method for determining the functional activity of ap50 for the complement alternative pathway of animal sera and use thereof

PendingCN122361329ABiotechnologyHemolysis
This application discloses a method for determining the functional activity of the alternative complement pathway (AP50) in animal serum and its application. The method includes: preparing a reaction buffer containing magnesium and calcium chelating agents; washing red blood cells with the reaction buffer and adjusting the red blood cell concentration to a preset range by measuring the absorbance value after complete lysis; serially diluting the animal serum to be tested with the reaction buffer, mixing it with a standardized red blood cell suspension, and incubating to induce a hemolytic reaction; after terminating the reaction, measuring the absorbance value of hemoglobin in the supernatant, calculating the hemolysis rate at each dilution, determining the serum dilution factor corresponding to 50% hemolysis, and using its reciprocal as the AP50 value. This application selectively activates the alternative pathway using a disclosed buffer formulation and eliminates batch-to-batch variability in red blood cells through absorbance standardization. It has advantages such as self-controllability, good reproducibility, low cost, and wide species adaptability, and can be widely used in immunological research and drug safety evaluation.
Owner:TIPMAX (SUZHOU) PHARM TECH CO LTD